| Literature DB >> 25264831 |
Mohamed Sakran1, Yasser Selim2, Nahla Zidan3.
Abstract
A new isoflavonoid, 5,6-dimethoxy-2',3'-methylenedioxy-7-C-β-d-gluco-pyranosyl isoflavone was isolated from the seeds of Lepidium sativum L. along with two known isoflavonoids, 7-hydroxy-4',5,6-trimethoxyisoflavone and 7-hydroxy-5,6-dimethoxy-2',3'-methylenedioxyisoflavone. The structures of all compounds were elucidated with NMR spectrometry. Compounds 1, 2 and the new isoflavonoid 3 were evaluated for their ability to reduce the hepatotoxicity induced by paracetamol in male rats by reducing the damage and toxicity effects on liver cells with a significant improvement of total antioxidant capacity, normalizing the levels of liver enzymes GSH, SOD, GPX, CAT and GST compared to control group.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25264831 PMCID: PMC6270865 DOI: 10.3390/molecules191015440
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of the isolated compounds.
Levels of serum ALT, AST, ALP and GGT of normal and experimental groups.
| Group | ALT(U/L) | AST(U/L) | ALP(U/L) | GGT(U/L) |
|---|---|---|---|---|
| Control Group 1 | 40 ± 1.5 | 43 ± 2.1 | 33 ± 2.4 | 60 ± 1.4 |
| Group2: Paracetamol | 70 ± 1.6 * | 80 ± 2.5 * | 71 ± 2.2 * | 117 ± 2.5 * |
| Group 3: Paracetamol + compound 1 | 60 ± 1.45 *# | 60 ± 2.2 *# | 53 ± 1.9 *# | 91 ± 2.4 *# |
| Group 4: Paracetamol + compound | 61 ± 1.33 *# | 62.2 ± 2.3 *# | 54 ± 1.8 *# | 95 ± 2.7 *# |
| Group 5: Paracetamol + compound | 50 ± 1.2 # | 53.5 ± 2.1 # | 39 ± 2.1 # | 72 ± 1.6 # |
Values are expressed as means ± SE; n = 10 for each treatment group; Significant difference from the control group at * p ˂ 0.05; Significant difference from paracetemol group at # p ˂ 0.05.
Changes in the levels of plasma total antioxidant capacity (mM/L) and liver MDA, SOD, GPx, CAT, GST and GSH of male albino rats in normal and experimental rats.
| Group | TAC (mM/L) | MDA | SOD units/g tissue | GPx units/g tissue | CAT mole/min/g tissue | GSH | GST |
|---|---|---|---|---|---|---|---|
| Group 1: Control | 1.2 ± 0.04 | 160 ± 3.23 | 60 ± 1.25 | 150 ± 1.5 | 0.8 ± 0.02 | 60 ± 1.3 | 2.2 ± 0.11 |
| Group 2: Paracetamol | 0.52 ± 0.02 * | 547 ± 9.46 * | 24 ± 2.4 * | 112 ± 1.2 * | 0.42 ± 0.01 * | 35 ± 0.85 * | 1.1 ± 0.01 * |
| Group 3: Paracetamol + compound 1 | 0.61 ± 0.03 *# | 320 ± 8.5 *# | 30 ± 2.1 *# | 118 ± 1.5 *# | 0.56 ± 0.01 *# | 40 ± 0.65 *# | 1.34 ± 0.01 *# |
| Group 4: Paracetamol + compound 2 | 0.65 ± 0.03 *# | 323 ± 9.11 *# | 33 ± 2.2 *# | 115 ± 1.4 *# | 0.55 ± 0.01 *# | 42 ± 0.54 *# | 1.37 ± 0.01 *# |
| Group 5: Paracetamol + compound 3 | 0.73 ± 0.02 # | 211 ± 5.22 # | 36 ± 1.5 # | 120 ± 6.5 # | 0.621 ± 0.01 # | 45.5 ± 1.2 # | 1.50 ± 0.8 # |
Significant difference from the control group at * p ˂ 0.05; Values are expressed as means ± SE; n = 10 for each treatment group; Significant difference from paracetemol group at # p ˂ 0.05.
NMR spectroscopic data of the isolated compounds.
| Position | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
| 1H | 13C | 1H | 13C | 1H | 13C | |
| 2 | 8.68s | 153.1 | 8.51s | 153.6 | 8.5s | 153.2 |
| 3 | - | 124.7 | - | 120.9 | - | 121.7 |
| 4 | - | 174.5 | - | 180.6 | - | 180.5 |
| 5 | - | 153.2 | - | 153.6 | - | 157.2 |
| 6 | - | 137.2 | - | 137.5 | - | 144.2 |
| 7 | - | 157.3 | - | 157.1 | - | 131.3 |
| 8 | 6.14s | 96.1 | 6.15s | 94.7 | 6.78s | 107.8 |
| 9 | - | 151.3 | - | 151.9 | - | 150.3 |
| 10 | - | 113.2 | - | 113.9 | - | 116.3 |
| 1' | - | 124.8 | - | 120.9 | - | 120.8 |
| 2' | 7.52 (d2.0) | 130.1 | - | 149.1 | - | 147.8 |
| 3' | 6.94 (d8.0) | 114.7 | - | 148.7 | - | 148.2 |
| 4' | - | 159.3 | 6.75 (d1.99) | 114.3 | 6.76 (d1.95) | 114.5 |
| 5' | 6.96 (d2,4) | 114.5 | 7.18 (d2.0) | 121.5 | 6.98 (d2.0) | 121.3 |
| 6' | 7.52 (d2.9) | 130.6 | 6.85 (d1.95) | 122.6 | 7.15 (d1.95) | 122.3 |
| 1'' | - | - | - | - | 4.82 (d,8.9) | 73.7 |
| 2'' | - | - | - | - | 3.75 (dd8.9,9.2) | 84.2 |
| 3'' | - | - | - | - | 3.37 (t8,9) | 72.2 |
| 4'' | - | - | - | - | 3.41 (t8.9) | 71.3 |
| 5'' | - | - | - | - | 2.94 (ddd6.2, 8.8) | 84.6 |
| 6'' | - | - | - | - | 3.81 (d12.3) 3.54 (dd6.2, 12.5) | 62.2 |
| OCH3-5 | 3.83s | 62.2 | 3.84s | 61.3 | 3.79s | 61.8 |
| OCH3-6 | 3.83s | 61.1 | 3.85s | 62.2 | 3.83s | 60.6 |
| OCH3-4' | 3.86s | 55.5 | - | - | - | |
| OCH2O-3',4' | - | - | 6.15s | 101.3 | 6.07s | 101.6 |
| OH-7 | 5.33s | - | 5.35s | - | - | - |
Figure 2HMBC correlation of compound 3.
Figure 3(A) normal liver section of rats; (B) liver sections in the paracetemol treated group exhibited cirrhosis, and macro nodular structures surrounded by fibrous tissue; (C) rats treated with paracetamol plus compound 1; (D) rats treated with paracetamol plus compound 2; (E) rats treated with paracetamol + compound 3. H&E stain (40×).